{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-237014","form_type":"8-K","ticker":"BNTC","cik":"0001808898","company_name":"Benitec Biopharma Inc.","filed_at":"2023-09-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.343033+00:00","generated_at":"2026-06-10T15:06:07.232515+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Benitec Biopharma increases CEO base salary to $655,200, Executive Director to $350,784","bullets":["Dr. Jerel Banks' (CEO) base salary raised to $655,200, effective Oct 1, 2023.","Megan Boston's (Executive Director) base salary raised to $350,784 (AUD converted at 0.64 USD/AUD), effective Oct 1, 2023.","Salary increases approved by Compensation Committee on September 13, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-237014","json":"https://secwatch.observer/filing/0001193125-23-237014.json","markdown":"https://secwatch.observer/filing/0001193125-23-237014.md","text":"https://secwatch.observer/filing/0001193125-23-237014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808898/000119312523237014/0001193125-23-237014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808898/000119312523237014/d552436d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T15:06:07.232515+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}